Anti-Epileptic Drugs For Pediatrics Market
Global Anti-epileptic Drugs for Pediatrics Market Size, Share & Trends Analysis Report by Drug Type (1stGeneration, 2nd Generation, and 3rd Generation), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global anti-epileptic drugs for the pediatrics market is anticipated to grow at a considerable CAGR of 4.4% during the forecast period (2022-2028). According to the World Health Organization (WHO), Epilepsy affects around 50 million people globally, making it one of the most frequent neurological disorders. Due to the illness being more common in youngsters than in adults, general practitioners are more likely to consult patients with epilepsy on a regular basis. Anti-epilepsy medications are in high demand due to the rising prevalence of other neurological illnesses such as anxiety and bipolar disorder. Furthermore, government measures to coordinate various epilepsy awareness campaigns and make treatment facilities available are projected to fuel market expansion throughout the projection period. In addition, continued pharmaceutical R&D operations are projected to drive market expansion by discovering novel therapeutic therapies. For instance, Tegretol is manufactured by Sandoz, which is a subsidiary of Novartis, also known as Carbamazepine is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.
Impact of COVID-19 Pandemic on Global Anti-epileptic Drugs for Pediatrics Market
With the growing number of COVID-19 globally, the market for anti-epileptic drugs for children is becoming more constrained. As the global economy battles the pandemic, its impact on the global exchange and store network is becoming clear from the rapid debilitation of global speculation streams. Strict regulatory measures imposed by governments around the world, as well as preventive measures to mitigate the impact of the outbreak, have resulted in a critical limitation in transportation, causing a thump on impact globally. This is creating a demand and supply gap, resulting in a decrease in the production of stress relief products. This pattern is necessary to infer the global anti-epileptic drugs for pediatrics market's vulnerability and solutions to resolve the inventory/request lop-sidedness.
Segmental Outlook
The global anti-epileptic drugs for pediatrics market is segmented based on the drug type, and distribution channel. Based on the drug type, the market is segmented into 1st generation, 2nd generation, and 3rd generation. Based on the distribution channel the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the online distribution channel segment is anticipated to propel the growth of the market over the forecast period, owing to the rising inclination of the population towards the internet. Thus, further driving the online penetration compared to offline or retail stores.
Global Anti-epileptic drugs for pediatrics Market Share by Drug Type, 2021 (%)
The 2nd Generation Segment is Anticipated to Hold a Prominent Share in the Global Anti-epileptic drugs for pediatrics Market
The Antiepileptic Medicines (AED) market is dominated by the 2nd generation drugs segment, Lyrica, Keppra, Bantel, and other second-generation medicines are examples. Lyrica has been a breakthrough medicine for the treatment of epilepsy, with the largest market share. It has demonstrated its ability to control seizures by slowing the brain's impulses. Lyrica, a drug developed by Pfizer, has stifled the epilepsy market until its patent expires in 2019. However, due to the drug's benefits, it is still in high demand. Other second-generation medicines have demonstrated their efficacy in lowering epilepsy symptoms. For instance, in January 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China for the treatment of partial-onset seizures in patients aged 12 and up.
Regional Outlooks
The global anti-epileptic drugs for pediatrics market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America dominates the global market due to considerable R&D efforts and the availability of approved 2nd generation antiepileptics,
Global Anti-epileptic drugs for pediatrics Market Growth, by Region 2022-2028
The Asia-Pacific Region is estimated to Hold the Major Share in the Global Anti-epileptic Drugs for Pediatrics Market
An increasing number of antiepilepsy drugs receiving CE mark approvals are anticipated to drive the demand for anticonvulsants drugs as well as expected regulatory approvals in Asia Pacific and penetration of key players in the region, together are projected to drive the epilepsy drugs market revenue in the Asia Pacific during the anticipated period. For instance; in July 2018 Dr. Reddy Laboratories Ltd. announced a distribution and co-promotion deal for Briviact in India with UCB S.A. Briviact is a drug that has been licensed for the treatment of partial-onset seizures in people aged 16 and up.
Market Players Outlook
The major companies serving the global anti-epileptic drugs for pediatrics market include Bausch Health Co. Inc., Cephalon Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2021, Biscayne Pharmaceuticals Inc., a clinical-stage biotechnology firm based in the US is focused on treating refractory kinds of focal epilepsy with its main product BIS-001, which has a new mode of action.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global anti-epileptic drugs for pediatrics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Anti-epileptic Drugs for Pediatrics Market
- Recovery Scenario of Global Anti-epileptic Drugs for Pediatrics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bausch Health Co. Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Cephalon Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline Plc
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Janssen Pharmaceuticals
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Pfizer Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Anti-epileptic Drugs for Pediatrics Market by Drug Type
4.1.1. 1st Generation
4.1.2. 2nd Generation
4.1.3. 3rd Generation
4.2. Global Anti-epileptic Drugs for Pediatrics Market by Distribution Channel
4.2.1. Hospital Pharmacies
4.2.2. Retail Pharmacies
4.2.3. Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Johnson & Johnson Service
6.2. Mylan N.V.
6.3. Novartis AG
6.4. Sanofi S.A.
6.5. Sumitomo Dainippon Pharma Co. Ltd.
6.6. Sunovion Pharmaceuticals Ltd.
6.7. Teva Pharmaceutical Industries Ltd.
6.8. UCB Pharmaceuticals Ltd.
6.9. Valeant Pharmaceuticals International Inc.
6.10. Zogenix Inc.
6.11. Zynerba Pharmaceuticals Inc.
1. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL 1ST GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL 2ND GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL 3RD GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
6. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY ONLINE DISTRIBUTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
13. EUROPEAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
19. REST OF THE WORLD ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET, 2021-2028 (%)
4. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
5. GLOBAL 1ST GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL 2ND GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL 3RD GENERATION ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
9. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS BY ONLINE DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. US ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
14. CANADA ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
15. UK ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
16. FRANCE ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
17. GERMANY ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
18. ITALY ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
19. SPAIN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
20. REST OF EUROPE ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
21. INDIA ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
22. CHINA ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
23. JAPAN ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
24. SOUTH KOREA ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF ASIA-PACIFIC ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD ANTI-EPILEPTIC DRUGS FOR PEDIATRICS MARKET SIZE, 2021-2028 ($ MILLION)
